Belamaf + VRd for Newly Diagnosed Transplant-Ineligible Myeloma Patients | Saad Usmani, MD

Hi, my name is Saad Usmani.

I'm the chief of the myeloma service at Memorial Sloan Kettering Cancer Center in New York.

And I'm also presenting here.

I've presented here the dreamm-9 update for the phase one study, in which belantamab mafodotin was combined with VRd in transplant ineligible older multiple myeloma patients.

So we have presented these data in the past, and this is the extended follow up.

Essentially what we're presenting is focusing on the 1.4mg/kg and 1.9mg/kg dosing cohorts.

Treatment was given in these cohorts initially at every four weeks.

And then it was extended to every, 6 or 8 weeks in the different cohorts to see if we can get the efficacy, but also reduce the likelihood of, ocular side effects.

So in about a third of the patients, we did see ocular side effects that persisted and required dose reductions, and delays.

But the overall responses were quite high.

You know, anywhere from 71 to 100% in the various cohorts and in MRD evaluable patients, the MRD rate was quite high, over 90%.

So infection was not a major concern.

I think the kinetics of response tell us that you can dose reduce and give less frequent dosing to patients and still get a good, potential outcome with a quadruplets strategy that employs a BCMA directed ADC in addition to VRd in these newly diagnosed transplant patients.

If our videos have helped you in any way and you're able to, please consider making a donation to help us continue this important work.

Your gift will go three times as far.

When we reached $500,000 by the end of the year,

every contribution, big or small, makes a difference,

and we're deeply grateful for your support.